The 340B Drug Savings Program

For 25 years, the 340B program has provided hospitals with financial help to expand access to life-saving prescription drugs and comprehensive health care services to low-income and uninsured individuals in communities across the country.

Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients. 340B hospitals use the savings they receive on the discounted drugs and reinvest them in programs that enhance patient services and access to care, as well as provide free or reduced priced prescription drugs to vulnerable patient populations.

The AHA Advocacy Alliance for the 340B Drug Pricing Program works to promote the value the 340B program provides to patients and communities and to oppose any efforts to scale back the program. Through email communications, conference calls and special briefings, the AHA 340B Advocacy Alliance keeps hospitals informed about the latest news and developments on the program, as well as actions hospital leaders can take to support the program.


Join the 340B AHA Advocacy Alliance   340B Drug Savings Program Tools & Resources

Related Resources

Letter
Member
The information below supplements the March 29, 2018 memorandum AHA’s outside counsel prepared regarding 340B claims submission during the legal ch
Testimony
Public
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions regarding “Effective Administration of the 340B Drug Pricing Program.”
Legal Documents
June 14, 2018 - Appellants provide two recent notices issue by Medicare Administrative Contractors (MACs).
Letter
On behalf of our nearly 5,000 member hospitals, health systems and other health care organizations, and our clinician partners – including more than 270,000…
Letter
Public
AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing…
Testimony
Public
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions: Examining Oversight Reports on the 340B Drug Pricing Program